申请人:Mackerell, JR. Alexander
公开号:US20120190708A1
公开(公告)日:2012-07-26
The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.
多重耐药病原体的出现需要寻找作用于先前未被开发的靶标的新抗生素。Nicotinate单核苷酸腺苷转移酶(NadD家族),是大多数细菌NAD生物合成的必需酶,被选为基于结构的抑制剂开发的目标。为此,发明人已经鉴定出小分子化合物,通过与酶上的新型抑制性结合位点相互作用来抑制细菌靶标酶,而对功能相当的人类酶没有影响。